Clinical Hematology International

<Previous Article In Issue
Next Article In Issue>
Volume 1, Issue 4, December 2019, Pages 220 - 228

The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study

Authors
Agoston Gyula Szabo1, *, Katrine Fladeland Iversen1, Sören Möller2, Torben Plesner1
1Department of Hematology, Vejle Hospital, Beriderbakken 4, 7100 Vejle, Denmark
2OPEN – Open Patient Data Explorative Network, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, J.B. Winsløws Vej 9 A, 5000, Odense C, Denmark
*Corresponding author. Email: agoston.gyula.szabo@rsyd.dk
Corresponding Author
Agoston Gyula Szabo
Received 3 June 2019, Accepted 21 July 2019, Available Online 12 August 2019.
DOI
10.2991/chi.d.190805.002How to use a DOI?
Keywords
Multiple myeloma; Treatment; Real-world data; Line of therapy
Abstract

In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011–2016 cohort. After initiation of treatment, the median decrease in the number of patients per each subsequent line of therapy was 22%. Lenalidomide-dexamethasone (n = 156), bortezomib-dexamethasone (n = 107), and bortezomib-lenalidomide-dexamethasone (n = 84) were the most commonly used regimens. The partial response or better rate was 78%, 58%, 55%, and 44% in lines of therapy one to four, respectively. The median (95% confidence interval [CI]) progression-free survival was 18 (15–22), 10 (8–13), 8 (7–10), and 6 (4–8) months in lines of therapy one to four, respectively. The median (95% CI) overall survival (OS) was 4.1 (3.7–4.8) years. Compared with the 2006–2010 cohort, patients in the 2011–2016 cohort had longer OS; 5.3 (4.7 to not reached) versus 3.4 (2.7–4.0) years, p < 0.0001. This was especially true in patients not treated with high-dose therapy and autologous stem cell transplantation; 4.7 (3.2–5.9) versus 2.6 (2.0–3.3) years, p = 0.0052. Patients in the 2011–2016 cohort were on treatment during a greater part of their life and had higher exposure to high-dose melphalan with autologous stem cell transplantation, lenalidomide, pomalidomide, daratumumab, and carfilzomib.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Clinical Hematology International
Volume-Issue
1 - 4
Pages
220 - 228
Publication Date
2019/08/12
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.190805.002How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Agoston Gyula Szabo
AU  - Katrine Fladeland Iversen
AU  - Sören Möller
AU  - Torben Plesner
PY  - 2019
DA  - 2019/08/12
TI  - The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
JO  - Clinical Hematology International
SP  - 220
EP  - 228
VL  - 1
IS  - 4
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190805.002
DO  - 10.2991/chi.d.190805.002
ID  - Szabo2019
ER  -